
Business: Verenium Corp, (VRNM) Verenium Corporation engages in the development and commercialization of cellulosic ethanol. It produces fuel-grade ethanol from an array of feedstocks, including sugarcane bagasse, energy crops, agricultural waste, and wood products. The company also develops and commercializes specialty enzymes for application within the biofuels, industrial, and health and nutrition markets. It possesses an array of enzymes derived from bio-diverse environments, as well as patented DirectEvolution technologies. The company’s biofuels products include Fuelzyme-LF, Fuelzyme-CX, Purifine, Amylase-T, and Termite enzymes; industrial processes products include Luminase PB-100 and Luminase PB-200, Purifine (edible oil), and Pyrolase enzymes; and health and nutrition products consist of proteins/enzymes, such as Phyzyme Phytase, QuantumPhytase, and Bayovac SRS, as well as antibodies. Verenium has alliances with Marubeni Corporation and Tsukishima Kikai Corporation, LTD.; Sid Martin Biotechnology Development Incubator University of Florida; The University of Florida; DuPont Bio-Based Materials; New Zealand Crown Research Institutes Scion and AgResearch; Syngenta AG; BASF; Cargill Health and Food Technologies; DSM; Danisco; Bayer; Merck & Co., Inc.; Medarex; and Xoma, as well as Fermic. The company was founded in 1994 and is headquartered in Cambridge, Massachusetts.
Industry Group: VRNM has been assigned to the Drug (Biomedical\Genetic) Industry Group.
Sales: VRNM has annual sales of $68,000,000
Sales Growth: VRNM has a Sales Growth of 37.00% per year.
Sales Per Share (SPS): VRNM has annual sales of $1.09 per share.
Price to Sales Ratio (P/S): VRNM has a P/S of 0.53.
Shares: VRNM has 63,000,000 shares of stock outstanding.
Market Capitalization: VRNM has a Market Capitalization of $36,000,000.



